Priyadarsiny Priyanka, Khattar Sunil K, Malik Renu, Udupa Venkatesha, Seshaiah Arigila, Rahman Shamsur, Shingatgeri Vyas Madhavrao, Bora Roop Singh, Saini Kulvinder Singh
Department of Biotechnology, Ranbaxy Research Laboratories, R & D III, Ydyog Vihar Industrial Area, Haryana, India.
J Toxicol Sci. 2008 May;33(2):163-73. doi: 10.2131/jts.33.163.
Drug-induced hepatotoxicity is one of the most common adverse events associated with drug withdrawal from the market. Elucidating the molecular mechanism of hepatotoxicity is essential to predict the safety of a new molecule. To examine genes involved in hepatotoxicity, we have used oligonucleotide CodeLink Bioarrays and determined the transcriptional profile of mice liver treated with hepatotoxic drug N-acetyl-p-amino-phenol (APAP) as well as its non-toxic analog N-acetyl-m-amino-phenol (AMAP). Out of 20,000 genes analyzed, 896 showed differential expression of > or = 2-fold (648 upregulated and 248 downregulated) within the liver of APAP treated mice as compared to control. In comparison to AMAP treated mice, 62 genes were upregulated and 70 genes were downregulated in mice liver after APAP treatment. Functional classification of these differentially expressed genes identified genes associated with stress response, cell cycle, growth inhibition, cell death, structural components, cell signaling and inflammation. Gene expression profile was further correlated with biochemical analysis and histopathological lesions. These data show that gene expression profiling would help in better understanding the molecular basis of drug-induced hepatotoxicity that will lead to rational development of safer drugs, particularly in pre-clinical stages.
药物性肝毒性是与药物退市相关的最常见不良事件之一。阐明肝毒性的分子机制对于预测新分子的安全性至关重要。为了研究参与肝毒性的基因,我们使用了寡核苷酸CodeLink生物芯片,并确定了用肝毒性药物N-乙酰对氨基酚(APAP)及其无毒类似物N-乙酰间氨基酚(AMAP)处理的小鼠肝脏的转录谱。在分析的20000个基因中,与对照组相比,在接受APAP处理的小鼠肝脏中,有896个基因表现出≥2倍的差异表达(648个上调,248个下调)。与接受AMAP处理的小鼠相比,APAP处理后小鼠肝脏中有62个基因上调,70个基因下调。对这些差异表达基因的功能分类确定了与应激反应、细胞周期、生长抑制、细胞死亡、结构成分、细胞信号传导和炎症相关的基因。基因表达谱进一步与生化分析和组织病理学病变相关联。这些数据表明,基因表达谱分析将有助于更好地理解药物性肝毒性的分子基础,这将导致更安全药物的合理开发,尤其是在临床前阶段。